Sorry, the video which you have requested is not yet processed.

Filter By:
Raquel Nunes, M.D., medical oncologist at the Washington Cancer Institute in Washington, D.C., discusses a study she co-authored that examined African-America​n women with breast cancer. The study showed these women frequently have a form of the disease that has a high risk of recurrence. The researc...
by:Agendia | 54 views
Noted oncologist Massimo Cristofanilli, M.D. discusses research he co-authored that compared molecular subtyping of breast cancer (with Agendia’s MammaPrint and BluePrint) to traditional clinical pathology methods. Molecular subtyping is used to better match patients to the most effective therapy. The study of more than 300 patients found that mole...
by:Agendia | 28 views
Breast cancer patient Cari Grundman explains how Agendia’s MammaPrint genomic test helped her get her disease treated appropriately. Cari’s physicians initially analyzed her cancer with the 21-gene genomic test. Unfortunately, Cari’s results fell in that test’s “intermediate” zone, meaning it was un...
by:Agendia | 35 views
Breast cancer patient Lisa Hill discusses her experience with Agendia’s MammaPrint molecular test for breast cancer recurrence risk. MammaPrint showed her cancer had a low risk of recurrence so she could safely avoid chemotherapy. Lisa describes how she watched a friend suffer with severe side-effects from chemotherapy and dreaded that her own life...
by:Agendia | 47 views
http://cance... Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation"​; ALK/ROS1 inhibitors, both those commercially available and those still in development. GRACEcast 282 Lung
by:cancergrace | 7 views
John Link, M.D., author of Take Charge of Your Breast Cancer and co-author of The Breast Cancer Survival Manual, explains the importance of determining the molecular subtype of a patient’s breast cancer. Molecular subtyping is used to guide patients to the most effective therapy for their form of cancer. Agendia’s BluePrint and MammaPrint genomic t...
by:Agendia | 34 views
Stefan Gluck, M.D., Ph.D., medical professor at the University of Miami, discusses a study he published in the journal Breast Cancer Research and Treatment. The study showed that women who have the common Luminal A molecular subtype of breast cancer generally receive little benefit from preoperative chemotherapy – but still have good outcomes at th...
by:Agendia | 30 views
Pat Whitworth, M.D., a surgical oncologist in Nashville, describes an ongoing study showing that Agendia’s BluePrint genomic test provides more accurate information about the molecular subtype of breast cancers than does conventional IHC-FISH pathology testing. The study determined which method was ...
by:Agendia | 18 views
Adam Brufsky, M.D., Professor of Medicine at the University of Pittsburgh Medical Center, describes an independent study that compared Agendia’s next-generation MammaPrint test to the first-generatio​n 21-gene test. Both instruments are genomic tests for breast cancer recurrence risk. The study found...
by:Agendia | 15 views
At the iwNHL 2014, Dr Rafael Fonseca interviews Prof Keith Stewart and Prof Leif Bergsagel, all doctors with an interest in myeloma, about the application of myeloma biology and therapies in lymphoma. Prof Stewart describes tumour heterogeneity and suggests a parallel between myeloma and indolent follicular lymphoma, where the presence of a more ag...
by:EMJ | 31 views

Top Tags

Please help us provide the best service.
I'm intersted in oncology videos because I'm a...

Different type of MD 
Other oncology Professional 
Something Else 

No Thanks(close window)
Membership has its privileges.
 I want the OncologyTube newsletter 

 I want to share videos & receive the newsletter 

I already have an account log me in.

username:   password: remember me

Sign In

Remember me
Forgot your password?
Not Yet a Member? Sign up for FREE here!
(Skip Ad)